Levi & Korsinsky has opened an investigation into Medpace Holdings over potential securities law claims, focusing on whether the company misrepresented the health of its clinical-trial bookings pipeline amid elevated cancellations and a weakening book-to-bill ratio. The probe follows Medpace’s disclosure of a Q4 2025 book-to-bill ratio of 1.04 and a subsequent share-price drop of about 15.9%.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medpace Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602180900PR_NEWS_USPR_____NY90102) on February 18, 2026, and is solely responsible for the information contained therein.